Big Pharma Pricing
The pharmaceutical industry is the #1 lobbying spender in Washington. Insulin costs $3 to manufacture and sells for $300+. Patent gaming keeps drug prices high while generic competition is blocked for decades.
Overview
The US pharmaceutical industry operates within a system that produces some of the highest drug prices in the world — Americans pay 2-3x more for prescription drugs than citizens of other developed nations. The industry has maintained this pricing power through aggressive lobbying (over $350 million annually, making it the #1 lobbying industry), patent manipulation, and a regulatory revolving door.
Insulin provides the starkest example. Discovered in 1921 and sold for $1 by its creators who believed it should be accessible to all, insulin now costs $300+ per vial in the US. The drug costs approximately $3-6 to manufacture. Three companies — Eli Lilly, Novo Nordisk, and Sanofi — control over 90% of the global insulin market and have been documented raising prices in lockstep.
Patent evergreening allows pharmaceutical companies to extend monopoly protection far beyond the original patent term. By making minor modifications to drugs — a new delivery mechanism, a different salt form, or a combination with another drug — companies obtain new patents that block generic competition. The FDA Orange Book lists over 40 patents on some drugs that were originally developed decades ago.
The Pharmacy Benefit Manager (PBM) system adds another layer of opacity. Three PBMs — CVS Caremark, Express Scripts, and OptumRx — control approximately 80% of the prescription drug market. These middlemen negotiate rebates from drug manufacturers that are not passed on to consumers, creating a system where the list price of drugs bears little relationship to what is actually paid at various points in the supply chain.
"Insulin was discovered in 1921 and sold for $1 by its creators, who believed it should be accessible to all. It now costs $300+ per vial. It costs $3-6 to manufacture. Three companies control 90% of the market."
Timeline
Insulin Price Escalation
The price of insulin increases by over 1,000% despite no significant changes to the drug.
Congressional investigations, pricing data
Purdue Pharma First Plea
Purdue Pharma pleads guilty to misbranding OxyContin, pays $635 million. (See Opioid Crisis topic)
Senate Drug Pricing Hearing
Senate Finance Committee grills pharma CEOs on pricing. Executives cite R&D costs, but data shows marketing spending exceeds R&D.
Senate Finance Committee
Inflation Reduction Act
IRA allows Medicare to negotiate prices on select drugs for the first time — but only 10 drugs initially, expanding to 20.
Key Players
Martin Shkreli
Raised the price of Daraprim 5,000% overnight, becoming the face of pharma greed. Later imprisoned for securities fraud.
Alex Azar
Served as HHS Secretary after being president of Eli Lilly's US operations, embodying the revolving door.
Richard Gonzalez
Oversaw AbbVie's strategy of filing over 100 patents on Humira, creating an impenetrable patent thicket that blocked biosimilar competition for over 20 years and generated $200+ billion in revenue.
Larry Merlo
Led CVS Caremark, the largest Pharmacy Benefit Manager, which controls drug pricing and formulary access for millions of Americans while operating with minimal transparency.
Billy Tauzin
As a Congressman, co-authored the Medicare Part D law that prohibited Medicare from negotiating drug prices. Left Congress and became president of PhRMA, the pharma lobbying group, at a reported $2 million annual salary.
The Patent Gaming System
Pharmaceutical companies have turned patent law into a weapon against generic competition. "Patent thickets" — dozens of overlapping patents on a single drug — create legal barriers that delay generic entry for years or decades beyond the original patent expiration.
AbbVie's Humira, the world's best-selling drug, was protected by over 100 patents. The company filed additional patents long after the drug's original development, extending its monopoly and generating $200+ billion in revenue. Generic biosimilar competition was delayed until 2023 — over 20 years after the drug's approval.
"Pay-for-delay" agreements, where brand-name manufacturers pay generic companies to delay market entry, cost consumers an estimated $3.5 billion per year according to the FTC.
The Bottom Line
The American pharmaceutical pricing system is not a free market — it is a managed market engineered to extract maximum revenue. Patent thickets block generic competition for decades. The law that created Medicare Part D explicitly prohibited the government from negotiating drug prices — a provision authored by a congressman who then left to lead the pharma industry's lobbying arm at a $2 million salary. The Inflation Reduction Act's 2022 reforms allow Medicare to negotiate on just 10 drugs initially, a fraction of the thousands on the market.
The fundamental structure remains intact: the industry that benefits most from high drug prices is the industry that spends the most to influence the lawmakers who set drug pricing policy. Americans pay 2-3x more for the same drugs than citizens of any other developed nation, and every attempt at meaningful reform has been diluted by the most powerful lobbying operation in Washington.
Primary Sources4 cited
Senate Finance Committee Drug Pricing Investigations
Investigations into pharmaceutical pricing practices and industry profits.
OpenSecrets Pharma Lobbying Data
Lobbying expenditure data showing pharma as the #1 lobbying industry.
FDA Orange Book
Patent listings for approved drugs, showing patent thickets.
CBO Drug Pricing Analyses
Congressional Budget Office analyses of drug pricing and reform proposals.
Connected Topics
More in MONEY & CORRUPTION
Continue investigating related topics in this category
Two massive document leaks — 11.5 million files from Mossack Fonseca and 11.9 million from 14 other firms — exposed how the world's wealthiest use offshore structures to hide assets and evade taxes.
The US lobbying industry spends over $4 billion per year purchasing legislative outcomes. Combined with post-Citizens United dark money, it has created a system where the formal democratic process is a performance layer over a private market for policy.
Sam Bankman-Fried built a $32 billion crypto empire, stole $8 billion in customer funds, donated $100 million to politicians, and was convicted on seven federal fraud counts — all by age 31.
Members of Congress and their families trade stocks in industries they regulate, with access to non-public information. The STOCK Act of 2012 was supposed to stop this. It didn't — it just required disclosure. And the disclosures show the trading continues.